CSPC Pharma Starts Phase Ib/II Trial of Cancer Drug Combination in China

MT Newswires Live
Yesterday

CSPC Pharmaceutical Group (HKG:1093) started a Phase Ib/II clinical trial in China of its experimental drug SYH2051 in combination with irinotecan liposome for the treatment of advanced solid tumors.

The multicenter, open-label trial will assess the safety and efficacy of the combination in patients with advanced solid tumors, according to a Monday Hong Kong bourse filing. Recruitment and screening are underway.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10